title: Cytomegalovirus retinitis during chemotherapy with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone.
authors.affiliation: University of New Mexico, Albuquerque, NM, USA.
authors.forename: Edward
authors.initials: E
authors.lastname: Libby
authors.forename: Sujana
authors.initials: S
authors.lastname: Movva
authors.forename: Dulcinea
authors.initials: D
authors.lastname: Quintana
authors.forename: Maryam
authors.initials: M
authors.lastname: Abdul-Jaleel
authors.forename: Arup
authors.initials: A
authors.lastname: Das
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000188:drug therapy / Q000209:etiology*; D003907:Dexamethasone / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D015774:Ganciclovir / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000175:diagnosis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy; D000069283:Rituximab; D014750:Vincristine / Q000009:adverse effects
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D015774:Ganciclovir